Show simple item record

dc.contributor.authorGargano, Emanuele M
dc.contributor.authorAllegretta, Giuseppe
dc.contributor.authorPerspicace, Enrico
dc.contributor.authorCarotti, Angelo
dc.contributor.authorVan Koppen, Chris
dc.contributor.authorFrotscher, Martin
dc.contributor.authorMarchais-Oberwinkler, Sandrine
dc.contributor.authorHartmann, Rolf W
dc.date.accessioned2016-07-06T09:39:32Z
dc.date.available2016-07-06T09:39:32Z
dc.date.issued2015
dc.identifier.citation17β-Hydroxysteroid Dehydrogenase Type 2 Inhibition: Discovery of Selective and Metabolically Stable Compounds Inhibiting Both the Human Enzyme and Its Murine Ortholog. 2015, 10 (7):e0134754 PLoS ONEen
dc.identifier.issn1932-6203
dc.identifier.pmid26230928
dc.identifier.doi10.1371/journal.pone.0134754
dc.identifier.urihttp://hdl.handle.net/10033/615613
dc.description.abstractDesign and synthesis of a new class of inhibitors for the treatment of osteoporosis and its comparative h17β-HSD2 and m17β-HSD2 SAR study are described. 17a is the first compound to show strong inhibition of both h17β-HSD2 and m17β-HSD2, intracellular activity, metabolic stability, selectivity toward h17β-HSD1, m17β-HSD1 and estrogen receptors α and β as well as appropriate physicochemical properties for oral bioavailability. These properties make it eligible for pre-clinical animal studies, prior to human studies.
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAnimalsen
dc.subject.meshCell Line, Tumoren
dc.subject.meshEnzyme Inhibitorsen
dc.subject.meshEstradiol Dehydrogenasesen
dc.subject.meshHumansen
dc.subject.meshMiceen
dc.subject.meshStructure-Activity Relationshipen
dc.title17β-Hydroxysteroid Dehydrogenase Type 2 Inhibition: Discovery of Selective and Metabolically Stable Compounds Inhibiting Both the Human Enzyme and Its Murine Ortholog.en
dc.typeArticleen
dc.contributor.departmentHelmholtz-Institute for Pharmaceutical Research Saarland (HIPS),Saarland 9 University, 66123 Saarbrücken, Germany.en
dc.identifier.journalPloS oneen
refterms.dateFOA2018-06-13T19:42:16Z
html.description.abstractDesign and synthesis of a new class of inhibitors for the treatment of osteoporosis and its comparative h17β-HSD2 and m17β-HSD2 SAR study are described. 17a is the first compound to show strong inhibition of both h17β-HSD2 and m17β-HSD2, intracellular activity, metabolic stability, selectivity toward h17β-HSD1, m17β-HSD1 and estrogen receptors α and β as well as appropriate physicochemical properties for oral bioavailability. These properties make it eligible for pre-clinical animal studies, prior to human studies.


Files in this item

Thumbnail
Name:
Gargano et al.PDF
Size:
320.6Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-sa/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/